M icroRNAs (miRNAs) are small noncoding RNAs with cell-type specific expression patterns that are released by cells into the circulation as part of membranous particles or protein complexes.
Dual oral antiplatelet therapy (acetylsalicylic acid
[ASA]+a P2Y 12 inhibitor) is commonly used for the management of non-ST-segment-elevation acute coronary syndromes (ACS) and ST-segment-elevation myocardial infarction. 5 ASA irreversibly inhibits cyclooxygenase 1 in platelets, thereby repressing thromboxane A 2 (TxA 2 ) synthesis and, consequently, platelet activation. Clopidogrel, prasugrel, and ticagrelor target the P2Y 12 receptor for ADP. However, interindividual variability in the platelet response to clopidogrel has been reported. Prasugrel and ticagrelor exhibit a more consistent antiplatelet effect and have shown benefits over clopidogrel in patients with ACS but also increase the risk of bleeding. 6, 7 It is currently unclear whether plasma levels of platelet-related miRNAs correlate with the residual platelet activity in patients with ACS and how different antiplatelet agents alter miRNAs.
In this study, we used RNA sequencing to characterize small RNAs in plasma. Then, we compared the effect of different antiplatelet agents and explored the association of small RNAs (miRNAs and YRNAs) with platelet function tests in patients with ACS. Moreover, we correlated their plasma levels to platelet activation markers in the prospective, population-based Bruneck study 3 and investigated whether a single-nucleotide polymorphism (SNP) that facilitates miR-126 processing 8 alters circulating miR-126 levels and platelet reactivity. These epidemiological observations were complemented by preclinical studies, assessing platelet function in mice on treatment with antagomiRs directed against miR-126 and by mechanistic studies measuring miR-126 targets.
Methods
An expanded Methods section is available in the Online Data Supplement.
Next-Generation Sequencing
Small RNA libraries were generated from non-normalized RNA (ranging from 375 pg to 1 ng) extracted from equal volumes of platelet-poor plasma (PPP) and platelet-rich plasma (PRP) from healthy human volunteers. Before library preparation, RNA was spiked with equal amounts of C. elegans miR-39 star (cel-miR-39*) to assist in normalization. Libraries were prepared using the small RNA library preparation kit version 2.0 (Illumina Cambridge Ltd) according to manufacturer's protocol with limited modifications. In brief, adapters were ligated to the 3′ end and 5′ end of RNA followed by cDNA preparation through reverse transcription. The cDNA was amplified with 12 cycles of PCR. The resulting library was purified using Agencourt Ampure XP beads (Beckman Coulter Inc). Libraries were quantified using Qubit (Life Technologies) and Bioanalyzer (Agilent). Because the total amount of libraries generated was limited, the libraries were mixed together in nonequimolar concentrations and sequenced on HiSeq2000 (Illumina Cambridge Ltd). Traces of the adapter (TGGAATTCTCGGGTGCCAAGG) at the end of the 22 nucleotides for miRNAs were removed using the Trimgalore software, allowing for 10% mismatch and discarding reads that, after adapter removal, became shorter than 15 nucleotides. More than 99.5% of the reads were reduced in size after adapter removal.
Platelet Spike-In
Human platelets and plasma were isolated from 4 healthy volunteers. Whole blood (16 mL) was drawn onto 4 mL of acid-citrate-dextrose (stock solution: 2.5 g sodium citrate, 2.0 g glucose, and 1.5 g citric acid, in 100 mL H 2 O) using a 21-gauge needle and 20-mL syringe and centrifuged at 190g for 30 minutes. All centrifugations were performed at room temperature without brake. The supernatant was transferred into a new tube. To prevent platelet activation, 10 nmol/L prostaglandin E1 (Sigma-Aldrich) and 10 μmol/L indomethacin (Sigma-Aldrich) were added. To deplete leukocytes, the supernatant was further centrifuged at 280g for 10 minutes. Leukocyte-depleted PRP (100 μL) was transferred to a 1.5-mL tube for RNA extraction. The remaining volume was transferred to a new tube and centrifuged at 1180g for 10 minutes to pellet platelets. The resulting supernatant was PPP. The platelet pellet was washed twice with modified Tyrode buffer (134 mmol/L NaCl, 2.9 mmol/L KCl, 0.34 mmol/L Na 2 HPO 4 , 12 mmol/L NaHCO 3 , 20 mmol/L HEPES, and 1 mmol/L MgCl 2 , pH 7.4; glucose (45 mg/50 mL) was added just before use, and the solution was warmed to 37°C in a water bath). Prostaglandin E1 and indomethacin were added during each wash at the concentrations mentioned above. The solution was centrifuged between washes at 1180g for 10 minutes. The final platelet pellet was resuspended in 1/20 of the volume of original PRP to obtain a 20× stock platelet solution. The 20× platelet solution was then spiked back into the PPP from the same donor to achieve 200%, 100%, 50%, and 5% spike-ins. Immediately after spiking PPP, QIAzol lysis reagent was added and RNA was extracted as described previously.
3,4

Systemic Inhibition of MiR-126-3p
Male C57BL/6J mice (Harlan), aged 8 weeks, were treated with cholesterol-conjugated antagomiR constructs (Fidelity Systems, Gaithersburg, MD) or sterile PBS. Sequences were designed to target miR-126-3p (5′-C*G*CAUUAUUACUCACGGU* A*C*G*A*-Chol*T-3′) or to serve as nontargeting control (5′-A*A*GGC AAG CUGACCCUGAA*G*U*U*Chol*T-3′). Intraperitoneal injections were performed on day 0, 1, and 2, in a dose of 25 mg/kg for the platelet function assays in whole blood and 40 mg/kg for the aggregometry experiments carried out in PRP. On day 7, mice were anesthetized using pentobarbital before collection of blood from the inferior vena cava using syringes containing lepirudin (Refludan, 25 μg/mL; Celgene, Windsor, United Kingdom). PRP was isolated as previously described. 10 Briefly, whole blood was diluted 1:1 with HEPES-Tyrode buffer (137 mmol/L NaCl, 20 mmol/L HEPES, 5.6 mmol/L glucose, 1 g/L BSA, 1 mmol/L MgCl 2 , 2.7 mmol/L KCl, and 3.3 mmol/L NaH 2 PO 4 ) before centrifugation (100g, 8 minutes, retention time).
Platelet Function in Mice
Platelet function tests were carried out as described previously. 11 Halfarea 96-well microtiter plates (Greiner Bio-One, Stonehouse, United Kingdom) were precoated with hydrogenated gelatin (0.75% wt/vol; Sigma, United Kingdom) in PBS to block nonspecific activation of blood. Vehicle or agonist solution (4 μL) was then added to each well: AA (0.03-0.6 mmol/L; Sigma, Poole, United Kingdom), Horm collagen (0.1-3 μg/mL; Nycomed, Linz, Austria), the protease-activated receptor 4 (PAR-4)-activating peptide AYPGKF amide (PAR4-AP, 50-100 μmol/L; Bachem, Bubendorf, Switzerland), and the stable TxA 2 mimetic U46619 (0.1-10 μmol/L; Cayman Chemical Company, Ann Arbor, MI). To each well, 35 μL of PRP or whole blood was added, and the plate was then placed onto a heated plate shaker (Bioshake IQ, Q Instruments, Jena, Germany) at 37°C for 5 minutes mixing at 1200 rpm. Where appropriate, light transmission of each well was determined using a 96-well plate reader (SunriseTM, Tecan, Männedorf, Switzerland) at 595 nm. Alternatively, samples were diluted 1:5 with an acid-citrate-dextrose solution (5 mmol/L glucose, 6.8 mmol/L trisodium citrate, and 3.8 mmol/L citric acid) before individual platelet counts of each were determined by flow cytometry. Platelets were labeled with allophycocyanin-conjugated anti-CD41 (clone eBioMWReg30) for 30 minutes before further dilution 1:50 in PBS containing 0.1% formalin (Sigma, United Kingdom), 0.1% dextrose, and 0.2% BSA and addition of 104 CountBright absolute counting beads (Life Technologies). Labeled, diluted blood was then analyzed using a FACSCalibur flow cytometer (BD Biosciences, Oxford, United Kingdom).
Results
Next-Generation Sequencing of Plasma MiRNAs
To characterize circulating small RNAs, libraries of small RNAs were generated from PRP and PPP for next-generation sequencing. The presence of platelets and the absence of leukocyte contamination in PRP samples were verified by qPCR for ITGA2B and CD45, respectively (Online Figure IA) . The quality of base calls is represented by consecutive boxplots for each position on the 100-nucleotide read (Online Figure IB) . The total number of digital reads correlated with the amount of RNA obtained from PPP and PRP (r p =0.94). Two peaks were observed across all 4 samples, 1 at 22 to 23 nucleotides corresponding to miRNAs and another centered around the 32 to 33 nucleotide range ( Figure 1A ), which aligned predominantly to RNY4, a noncoding RNA, on chromosome 7. The 25 most abundant small RNAs in each sample are shown in Figure 1B . At a threshold of 0.4 reads per million and without distinguishing between isomiRs, 224 miRNAs were consistently identified in all samples (Online Table I ). There was a good correlation for the number of reads per miRNA (Online Figure IC) . Coverage of RNY4 was predominantly observed on the 5′ end, with some additional fragments from the 3′ end. Sequences derived from other RNY genes were also detected, although at much lower read counts: for RNY1 and RNY5, like RNY4, mostly, 5′ fragments were found; for RNY3, the 3′ fragments were more abundant (Online Figure II) . Two hundred three of 224 miRNAs and both RNY4 fragments were detected at higher levels in PRP than PPP, suggesting that most circulating small RNAs are present in platelets (Online Figure III) .
Effect of Antiplatelet Therapy
We have previously reported that antiplatelet therapy reduces plasma levels of platelet-related miRNAs, including miR-126 and miR-223. 4 Ninety-two miRNAs were measured using custom-made Exiqon LNA qPCR plates. The plate layout has been published previously 4 and is shown in Online 
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a principal component analysis, the interindividual variability in plasma miRNA profiles decreased with prolonged platelet inhibition 4 ( Figure 2A ), reinforcing the concept that platelet activity is an important determinant of the plasma miRNA pool. To explore how different antiplatelet agents affect plasma miRNAs, the same 92 miRNAs were screened in a closely matched cohort of patients with ACS who were either on ASA only (n=8), ASA+clopidogrel (n=8), ASA+prasugrel (n=8), or ASA+ticagrelor (n=8) for 30 days after the acute event. In the principal component analysis, no clear separation was obtained between the different antiplatelet agents, but the least interpatient variability was observed in the ASA+prasugrel group ( Figure 2B ).
Correlation to Platelet Function in Patients With ACS
Next, platelet-related miRNAs (Online Figure IV) and abundant plasma YRNA fragments were measured by individual qPCR assays in the ACS patient cohort who had undergone detailed assessment of platelet function (n=125; Online Table III) . 
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Evidence for Platelet Origin
Although all candidate miRNAs were present in platelets (Online Figure IV) , some reflected platelet activation better than others. To determine to what extent platelets may contribute to circulating miRNA and YRNA levels, we reconstituted PPP with washed platelets. Platelets were isolated from PRP and spiked back into PPP corresponding to 5%, 50%, 100%, or 200% of the initial volume ( Figure 4A ). For miR-126 and miR-223, a significant linear increase was observed with increasing platelet content ( Figure 4B ). As expected, the liver-specific miRNA, miR-122, was not affected by addition of platelets. Notably, miR-126 showed the greatest dependency on platelets in comparison with 21 other miRNAs ( Figure 4C ). This spike-in experiment provides further evidence for platelets being a major source of circulating miRNAs, including miR-126, which was previously implicated to be of endothelial origin.
12-14
Levels of RNY4 fragments were also strongly affected by addition of platelets ( Figure 4C ). Unlike miRNAs, however, RNY4 was not associated with argonaute-2 complexes in MEG-01 cells, a human megakaryoblastic cell line (Online Figure V) .
MiR-126 and Platelet Function in the General Population
MiRNAs and RNY4 fragments were measured in the Bruneck study (n=669) and correlated to the platelet activation markers 15 platelet factor 4 (PF4), pro-platelet basic protein (PPBP), and P-selectin as quantified by ELISA ( Figure 5A ). Substantial positive correlations of miRNAs and RNY4 fragments with all 3 platelet-activation markers were observed in plasma. These were more pronounced for the platelet-specific proteins PF4 and PPBP than for P-selectin, which is shed from platelets and endothelial cells. 16, 17 The liver-specific miRNA, miR-122, and other miRNAs, such as miR-150, showed no or considerably weaker correlations with platelet activation markers ( Figure 5A ). Accordingly, there was a striking correlation between the platelet dependency of miRNAs in the spike experiment and the correlations of miRNAs with platelet activation markers in the general population (r=0.92-0.94; Figure 5B ; Online Figure VI ). RNY4 fragments were strongly correlated with platelet-derived plasma miRNAs ( Figure 5C ), suggesting a common platelet origin.
Although circulating miRNAs have been shown to be affected by disease state, cardiovascular risk factors, and drug treatment, the influence of genetic variability, especially SNPs, on miRNA expression and function is poorly understood. Thus far, only 1 functional SNP has been described for miR-126 ( Figure 6A ): the primary sequence of human miR-126 contains a SNP (dbSNP: rs4636297) downstream of the pre-miR sequence. 8 The genotype of this SNP has been shown to affect the processing of pri-miR-126: pri-miR-126 encoded by the major G allele is processed to a lesser extent than pri-miR-126 encoded by the minor A allele. In the Bruneck cohort (Online Table IV) , there was a trend toward higher miR-126 levels in individuals homozygous for the minor allele (AA genotype), which facilitates processing of miR-126, compared with the GA+GG genotypes in serum (+4.4%; P=0.050) and in plasma (+6.9%; P=0.099; Online Figure  VII) . Importantly, the AA genotype was associated with higher plasma levels of platelet activation markers: PF4 (P=0.002), PPBP (P<0.001), and P-selectin (P=0.099; Figure 6B ). To compare the effect on platelet proteins to other plasma proteins, we
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February 5, 2016 measured 219 proteins, using mass spectrometry for detection of high-abundant proteins (n=84) and proximity extension assays for detection of low-abundant proteins (n=132), as well as ELISA (n=3). Of 61 proteins whose levels are significantly associated with the AA genotype (Online Figure VIII) , PPBP and PF4 showed the second and third highest fold change (mean ratios, AA versus GA+GG of 1.49 and 1.47, respectively; Online Table  V) . The proteins associated with the AA genotype also showed an enrichment of the gene ontology term annotation platelet activation (P=0.019; Online Figure VIII ).
MiR-126 and Platelet Function in Mice
The genetic associations of a SNP within miR-126 with parameters of platelet function prompted us to further investigate the role of miR-126 in platelet activation. It has recently been reported that oligonucleotides with a phosphorothioate backbone modification (minimum length of 18 nt) can activate platelets. 18 Thus, we incubated human PRP with fully phosphorothioate-modified LNAs, as well as antagomiRs with 2 and 4 phosphorothioate-modified nucleotides at the 5′ and 3′ ends, respectively. None of the tested oligonucleotides with cholesterol modification induced platelet aggregation (Online Figure  IX) . Next, C57BL/6J mice were injected with PBS, a control antagomiR or antagomiR-126-3p at 25 mg/kg IP, for 3 consecutive days and euthanized at day 7 ( Figure 7A ). The knockdown of miR-126 was confirmed in blood samples by qPCR (Online Figure X) . Whole blood was treated with different concentrations of agonists: AA, collagen, PAR4-AP, and the TxA 2 analog U46619 ( Figure 7B ). The aggregation response to AA and U46619 was significantly reduced in platelets from mice treated with antagomiR-126-3p. At antagomiR doses of 25 mg/kg, however, there was no effect on platelet aggregation in response to collagen or PAR4-AP. Thus, we repeated the experiment with a higher antagomiR concentration (40 mg/kg IP). Again, Figure 4 . Platelet spike-in experiment. A, Schematic summary of workflow. B, Dependence of miR-126, miR-223, and miR-122 levels on platelet spike-in. C, P values for the dependence of levels of 22 microRNAs and 2 RNY4 fragments on platelet spike-in. RNAs marked in bold were tested in the acute coronary syndrome cohort. The grey line represents the significance threshold for a P value of 0.05 after Bonferroni correction. B and C, Results shown are derived from linear mixed models featuring fixed effects for platelet spike-in in categorical form (B) or in continuous form (C), random intercepts for subjects, and a general (unconstrained) covariance structure. PPP indicates platelet-poor plasma; and PRP, platelet-rich plasma. 
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the inhibition of miR-126 was confirmed by qPCR (Online Figure X) . To further address the effect of miR-126 in platelets and to minimize a potential influence of other cell types, PRP was used instead of whole blood for platelet aggregation. AntagomiRs against miR-126-3p blocked platelet aggregation induced by 0.6 mmol/L AA ( Figure 7C ) and led to a significant reduction of aggregation in response to 50 μmol/L PAR4-AP. The attenuated response to 0.3 μg/mL collagen failed to reach statistical significance. No differences in platelet aggregation were observed at higher agonist concentrations of PAR4-AP (100 μmol/L) and collagen (3 μg/mL; data not shown).
Targets of MiR-126 in Platelets
To explore potential mechanisms, we measured the expression levels of known miR-126 targets with a role in platelet function alongside platelet-related genes (Online Table VI ). We observed reduced expression of the P2Y 12 receptor in whole blood of antagomiR-126-3p-treated mice ( Figure 8A ). In a human megakaryoblastic cell line (MEG-01), mimics or LNA inhibitors of miR-126-3p (Figure 8B and 8C; Online Figure XI ) regulated ADAM9, a confirmed target of miR-126 that has been shown to affect collagen-induced platelet aggregation ( Figure 8D ). 19 Thus, miR-126 alters gene expression in megakaryocytes.
Discussion
In this study, miRNA measurements were performed in 669 subjects of a population-based study, as well as in 125 patients with ACS. The study correlates miRNAs with platelet activation markers in the general population and with the residual platelet activity in patients with ACS on antiplatelet therapy. Most but A and C, Tile color codes for direction and magnitude of correlation, whereas tile text gives its sign and first 2 decimal digits.
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not all abundant platelet miRNAs were positively correlated with the VerifyNow P2Y 12 and VASP assays, which are standardized assays for assessing the effects of P2Y 12 inhibitors. In addition, we show an association of plasma YRNAs with platelets and that inhibition of miR-126 attenuates platelet aggregation in response to low but not high agonist concentrations.
Platelet Dependency of Small RNAs in Plasma
To demonstrate the platelet dependency of our candidate miRNAs, washed platelets were isolated from PRP and spiked back into PPP. This spike-in experiment rules out a cellular contamination, which can hamper direct comparisons between PRP and PPP and provide further evidence that the selected miRNAs, including miR-126, are genuine platelet miRNAs. 4 Furthermore, we provide evidence that RNY4 fragments in plasma also originate from platelets. YRNA fragments are enriched in exosomes. 20, 21 Our next-generation sequencing data confirm that RNY4 fragments are abundant in plasma. 22 Unlike miRNAs, however, RNY4 fragments were not present in the Ago2 (argonaute 2 protein) complexes of MEG-01 cells. 23, 24 Recently, YRNA fragments were implicated as biomarkers for coronary artery disease. 25 Changes in circulating levels were attributed to apoptotic macrophages, which generate and secrete YRNA fragments. 25 In contrast, our data suggest that platelets are a major source of circulating YRNA fragments, and cellular origin has to be taken into account if YRNA fragments are considered as potential biomarkers for cardiovascular disease. The function of YRNA fragments remains unknown, but it has been suggested that YRNA fragments, including RNY4 5′, act as small guide RNAs for tRNase Z L , forming a tRNA-like duplex with a target RNA, thereby enabling its hydrolysis. 26 This mechanism has been shown for synthetic target RNAs in vitro, and it remains to be seen whether YRNA fragments can act as guide RNAs for tRNase Z L in vivo.
Platelet MiRNAs in Patients Post ACS
Plasma was taken 30 days after the acute event when the inflammation associated with the acute injury has receded and antiplatelet drugs had been administered for a month. Importantly, none of the patients with ACS had received heparin at the time of sampling. 27 ,28 Levels of miR-126 and other platelet-related miRNAs showed a positive correlation with the VerifyNow P2Y 12 and VASP phosphorylation assays. VerifyNow P2Y 12 is a commercial assay that uses whole blood to monitor P2Y 12 inhibition. 29 The VASP assay is considered to be among the most specific assays to monitor P2Y 12 inhibition because it does not rely on coactivation of the P2Y 1 receptor by ADP. 30 In contrast, optical aggregometry is performed on isolated platelets. Theoretically, aggregometry responses to ADP and the VASP, and Verify Now P2Y 12 assays assess the same parameter: P2Y 12 receptor activation. However, the variability of the aggregometry results in isolated platelets being higher compared with tests performed in whole blood may explain the loss of associations with plasma miRNAs. Previous studies have suggested that VerifyNow P2Y 12 and VASP assays are more discriminating of clopidogrel response and its genetic influences compared with light transmittance aggregometry, and there are only moderate correlations between the different platelet function assays. 30, 31 Moreover, aspirin is such a potent inhibitor of the platelet response to AA that any variation between patients is expected to be low. Aspirin inhibits the production of TxA 2 . Clopidogrel and prasugrel act by blocking the platelet P2Y 12 receptor. 5, 29 Thus, their mechanisms are complementary. Clopidogrel and prasugrel are both thienopyridine prodrugs that are converted via hepatic CYP (cytochrome P450 enzyme) isoenzymes to their active metabolite, but prasugrel is more efficiently converted to its active form and so achieves more reliable P2Y 12 inhibition. Ticagrelor is a novel P2Y 12 receptor antagonist, but its clinical profile, both in terms of efficacy and adverse events, differs from that of the thienopyridine prodrugs. 32 Ticagrelor is also supposed to have a dual mode of action as its P2Y 12 antagonism is complemented by inhibition of adenosine cell uptake via inhibition of the equilibrative nucleoside transporter 1, thereby increasing extracellular adenosine level and mediating adenosine-receptor activation.
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Platelet MiRNAs and Platelet Activation in the General Population
It is currently unclear to what extent platelet miRNAs are mechanistically involved in platelet activation. A SNP (rs4636297) in the miR-126 locus has previously been demonstrated to affect the expression of mature miR-126 in cells overexpressing the different variants of pri-miR-126. An effect on endogenous miR-126 levels has not been investigated thus far. 8 In plasma and serum from the Bruneck cohort, we observed a trend toward higher levels of circulating miR-126 in individuals carrying the minor allele (AA genotype), which facilitates the processing of pri-miR-126. Importantly, the SNP genotype affected the plasma concentrations of 3 platelet activation markers: PF4 (P=0.002), PPBP (P<0.001), and P-selectin (P=0.099) were all positively correlated with the AA genotype. Moreover, for proteins showing an association with the AA genotype in a panel of 219 plasma proteins measured in the Bruneck cohort, there was a significant enrichment of proteins linked to platelet activation (P=0.019; Online Figure VIII ). These genetic associations, however, await confirmation in independent cohorts. MiR-126 is abundant in endothelial cells and platelets. 3 Although miR-126 is known to be an important regulator of endothelial cell function, 12, 33 its role in platelets is unknown. It is, therefore, conceivable that higher miR-126 levels in individuals with the AA genotype influence platelet activity either directly by changing platelet function or indirectly by affecting endothelial cells. Recently, the A allele of SNP rs4636297 has been shown to be associated with sightthreatening diabetic retinopathy in patients with type II diabetes mellitus, 34 corroborating the relevance of genetic variability of miRNAs for susceptibility to disease.
MiR-126 and Platelet Aggregation in Mice
Despite numerous reports on miRNAs, surprisingly little is known about their function in platelets. MiR-223 targets the P2Y 12 receptor. 35 MiR-223-deficient mice form larger thrombi and have a delayed clot retraction compared with wild-type mice. 36 Platelets of miR-223-deficient mice display increased aggregation in response to thrombin and collagen but not to fibronectin and the TxA 2 analog U44619. MiR-96 regulates VAMP8/endobrevin, a protein involved in platelet granule secretion that is upregulated in hyper-reactive platelets. 37 Our experiments demonstrate that inhibition of miR-126 in mice attenuates platelet aggregation in response to AA, U44619, and PAR4-AP. Collagen-induced platelet aggregation may also be affected, but we did not obtain statistical significance, probably because of low numbers. Platelet aggregation was reduced in whole blood and in PRP. Thus, the involvement of other cell types is less likely. Moreover, MEG-01 cells express miR-126 in abundance, and mimics of miR-126 reduced the expression of ADAM9, whereas inhibition of miR-126 had the opposite effect. ADAM9 is a predicted and experimentally confirmed target of miR-126 that attenuates the adhesion of platelets to collagen. 19 Given its function as a protease of the ADAM family, it may alter the platelet response by cleaving membrane proteins. In whole blood from antagomiR-treated mice, ADAM9 was not differentially expressed. This is expected because ADAM9 is present in many other blood cells that lack miR-126 and therefore are not affected. Notably, the expression of the P2Y 12 receptor was reduced in the blood of antagomiR-126-3p-treated mice. P2Y 12 levels are much higher in platelets than in leukocytes 38 and erythrocytes. 39 Thus, the latter finding may, at least in part, explain why platelets from antagomiR-126-3p-treated mice display an attenuated aggregation response: the aggregation responses to strong platelet agonists, such as collagen, thrombin receptor-activating peptides, and particularly, either TxA 2 (generated from AA) or its mimetic U46619, are amplified by ADP, which is released from the platelet dense granules in response to the agonists and activates the P2Y 12 receptor. On the other hand, higher concentrations of these agonists or less effective P2Y 12 inhibition or deficiency allow a more robust platelet aggregation response. P2Y 12 activation may also contribute to the generation of TxA 2 from AA.
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Study Limitations
Causality cannot be inferred from associations of miRNAs with platelet function tests in patients with ACS. Although recent studies implicated miR-126 in atherogenesis, 41, 42 and miR-223 has been used for categorization of patients as responder and nonresponder to the P2Y 12 inhibitor clopidogrel, 43 larger cohorts with prolonged follow-up are required to determine whether miRNA levels are associated with clinical outcomes in patients with ACS. Because the P2Y 12 receptor plays such an important role in platelet reactivity, relationships between the extent of P2Y 12 receptor inhibition and miRNA levels have to be further explored in future studies. Similarly, the reported association of a SNP for miR-126 with platelet activation markers requires replication in independent cohorts. MiR-126 is also abundant in endothelial cells, and indirect effects on platelets cannot be excluded. On the other hand, gene expression in MEG-01 cells may be subject to different regulation mechanisms than in primary megakaryocytes and platelets, that is, in undifferentiated MEG-01 cells, P2Y 12 expression is not detectable.
Conclusions
Numerous studies have demonstrated the importance of platelet reactivity in the risk of clinical events, such as stent thrombosis after percutaneous coronary intervention or recurrent arterial thrombotic events after ACS. Exciting opportunities exist to further pursue platelet miRNAs as potential biomarkers for treatment response in patients with ACS. 44 MiRNAs can be measured in frozen samples, which could offer a potential advantage compared with other platelet function tests currently available. Besides their biomarker potential, some miRNAs, such as miR-126 and miR-223, 36 may also regulate platelet reactivity. What Is Known?
• Plasma microRNAs (miRNAs) are highly correlated.
• Platelets contain and release miRNAs.
• Platelet inhibition reduces miRNA levels in platelet-poor plasma.
What New Information Does This Article Contribute?
• Besides miRNAs, YRNA fragments in plasma are also platelet derived.
• Platelet miRNAs and YRNA fragments correlate with indices of platelet function in patients on dual antiplatelet therapy.
• MiRNA-126 alters platelet activity.
This study provides evidence for platelets being a source of miRNAs and YRNA fragments in plasma. A strong platelet dependency of miRNAs and YRNA fragments was observed in a spike-in experiment. There was also a striking correlation of miRNAs and YRNA fragments with platelet activation markers in the general population. Plasma miRNA and YRNA levels are associated with residual platelet activity in patients on dual antiplatelet therapy. MiRNA-126, previously considered to be endothelial specific, is present in platelets and in a human megakaryoblastic cell line. A single-nucleotide polymorphism that facilitates processing of miRNA-126 increases plasma levels of platelet activation markers. Treatment with antagomiRs to miRNA-126 reduces platelet activation in mice. MiRNAs may not just be markers of platelet activity but also alter their function, most probably by influencing gene expression in megakaryocytes.
ONLINE METHODS
RNA Isolation, Reverse Transcription (RT) and Pre-amplification.
TotalRNA including small RNAs was extracted using the miRNeasy kit (Qiagen).
1,2 For miRNA analysis from plasma samples, a fixed volume of 3 µl of the 25 µl RNA eluate was used as input in each RT reaction. For RNA from tissues or cells, 100 ng RNA were used for the RT reaction. An RT reaction and pre-amplification step were performed as described previously. 1, 2 In brief, miRNAs were reversely transcribed using Megaplex Primer Human Pool A v2.1 (Life Technologies). RT reaction products were further amplified using the Megaplex PreAmp Primers A v2.1 (Life Technologies). Both RT and PreAmp products were stored at -80 °C. YRNAs were reversely transcribed using the TaqMan MicroRNA RT Kit (Life Technologies) and specific RT primers provided with custom Taqman assays for the following sequences:
For the analysis of gene expression, RNA (100-1000 ng) was reversely transcribed using the High-Capacity cDNA Reverse Transcription Kit (Life Technologies) according to the manufacturer's instructions.
Custom-designed qPCR Plates. The expression profile of miRNAs in ACS patients treated with ASA, ASA + clopidogrel, ASA + ticagrelor or ASA + prasugrel (n=8 for each treatment) was assessed using custom-made Exiqon LNA qPCR plates (Exiqon Life Sciences). A total of 92 miRNAs was measured using the miRCURY LNA Universal RT microRNA PCR protocol which is a two-part protocol consisting of first-strand cDNA synthesis followed by qPCR amplification. For cDNA synthesis, 2 µl of 5x Reaction buffer were combined with 1 µl of 10x Enzyme mix and 2 µl of RNA to a final volume of 10 µl. RT was performed by incubating the samples at 42 °C for 1 h and subsequent heat inactivation of the enzyme at 95 °C for 5 min. RT products were stored at -20 °C. For PCR amplification, 2x SYBR® green master mix (Exiqon Life Sciences) was used for cDNA with the reaction conditions being identical as described for TaqMan qPCR assays. MiRNAs with a Ct higher than 35 in all samples were considered undetectable and omitted from the analysis. The remaining miRNAs were normalized to the average of all endogenous miRNAs.
Individual qPCR Assays. Individual miRNAs were measured by TaqMan miRNA assays as described previously.
1,2 2.25 µl diluted pre-amplification product (plasma samples) or 2.25 diluted RT product (equivalent to 1 ng/µl RNA) were combined with 0.25 µl TaqMan miRNA Assay (20x) (Life Technologies) and 2.5 µl TaqMan Universal PCR Master Mix No AmpErase UNG (2x) to a final volume of 5 µl. YRNA fragments were measured in the RT product (without preamplification) using custom-made small RNA Taqman assays. QPCR was performed on a ViiA7 thermocycler (Life Technologies) at 50 °C for 2 min, 95 °C for 10 min, followed by 40 cycles of 95 °C for 15 sec and 60 °C for 1 min. Relative quantification was performed using the 2 -ΔΔCt method. Exogenous miRNA (cel-miR-39) was used as a spike-in normalization control for plasma samples. MiRNAs in tissue and cell samples were normalized to endogenous U6 RNA.
Enzyme-linked Immunosorbent Assays (ELISA).
The levels of P-selectin, pro-platelet basic protein and platelet factor 4 were measured in plasma samples from the Bruneck cohort using DuoSet ELISA Development kits (catalogue numbers DY137, DY393, DY795) and the DuoSet Ancillary Reagent Kit 2 (R&D Systems, Minneapolis, USA) according to the manufacturer's instructions. Absorbance at 450 nm was measured on a Tecan Infinite 200 Pro plate reader (Tecan Group Ltd., Männedorf, Switzerland) using 570 nm as a reference wavelength. Results were calculated using a four-parameter logistic fit.
Cell Culture and transfection. Cells from the megakaryoblastic leukemia cell line MEG-01 (ATCC) were cultured in RPMI-1640 (Life Technologies) supplemented with 10% FCS, 100 U/ml penicillin and 100 µg/ml streptomycin at 37 °C in a humidified atmosphere of 95% air / 5% CO 2 . For transfection, 1.5x10 5 cells were washed twice and then seeded in 6-well plates in blank RPMI-1640. MicroRNA mirVana™ mimics were synthesized by Life Technologies and MiRcury™ LNA-antimiRs by Exiqon. The following sequences were used:
LNA-126-3p: CGCATTATTACTCACGGTA LNA-control: TAACACGTCTATACGCCCA hsa-miR-126-3p mimic: UCGUACCGUGAGUAAUAAUGCG Control mimic: sequence not specified.
LNA inhibitors and miRNA mimics were transfected at a final concentration of 20 nmol/L and 50 nmol/L respectively, using Lipofectamine RMAiMAX (Invitrogen) according to the manufacturer's recommendations. 48 h after transfection, cells were lysed in QIAzol for RNA extraction.
Argonaute-2 Immunoprecipitation. Immunoprecipitation of ribonucleoprotein was carried out, as previously described 3 , in MEG-01 cells. Briefly, 50-100 million cells were lysed in 500 µl ice cold polysome lysis buffer (5 mM MgCl 2 , 100 mM KCl, 10 mM Hepes, pH 7.0, 0.5% Nonidet P-40) with freshly added 1 mM DTT, 100 U/ml Rnase inhibitor (Life Technologies) and 1× complete mini EDTA-free protease inhibitor cocktail (Roche) for 15 min. Centrifugation was performed at 14,000 × g at 4 °C for 10 min. The supernatant was mixed with 500 µl of ice-cold NT2 buffer (50 mM Tris, pH 7.4, 150 mM NaCl, 1 mM MgCl 2 , 0.05% Nonidet P-40) containing freshly added 200 U/ml Rnase inhibitor, 0.5% vanadyl ribonucleoside, 1 mM DTT, 15 mM EDTA and 50 µl mouse anti-human Ago2 (Abcam) coated sepharose G beads (Life Technologies). Incubation was carried out overnight at 4 °C on a rocking platform. On the following day, the beads were washed five times with ice-cold NT2 buffer and beads were used for RNA isolation.
SNP Genotyping. The Bruneck cohort (follow-up 1995) was genotyped for SNP rs4636297 using the KASPar method (Competitive Allele Specific PCR SNP genotyping system) (LGC Ltd., Teddington, UK).
Multiple Reaction Monitoring (MRM).
PlasmaDive kits (Biognosys AG) were used to profile plasma proteins by mass spectrometry in the Bruneck Study. Plasma samples were processed according to the manufacturer's instructions with one exception: peptide standards were spiked in before and not after tryptic digestion and C18 clean-up. Briefly, 10 µl of plasma samples were denatured, reduced and alkylated. 20 µg of proteins were spiked with 100 authentic heavy peptide standards. Seven proteins were below the limit of detection. An in-solution digestion was performed overnight. After solid phase extraction with C18 spin columns (96-well format, Harvard apparatus), the eluted peptides were dried using a SpeedVac (Thermo) and resuspended in 40 µl of LC solution. The samples were analyzed on an Agilent 1290 LC system interfaced to an Agilent 6495 Triple Quadrupole MS. 10 µl samples were directly injected onto a 25 cm column (AdvanceBio Peptide Map 2.1 x 250 mm) and separated over a 23 min gradient at 300 µl/min. The data were analyzed using Skyline software version 3.1 (MacCross Lab) and protein concentrations were calculated using the heavy/light (H/L) ratio.
Proximity Extension Assays. Low abundant plasma proteins were analyzed in plasma samples of the Bruneck study using Olink Proseek proximity extension assays (Proseek Multiplex CVD I and Inflammation I panels) as previously published.
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Effect of MiRNA Inhibitors. Citrate-anticoagulated human blood was centrifuged for 15 min at 175 × g, from which PRP was extracted. The remaining blood was then centrifuged at 10000 × g for 2 min to obtain PPP. 25 µl of PBS, ADP (50 µM), collagen (10 mg/ml), LNA (10 µM) or antagomiR (10 µM) was added to 225 µl of PRP. Platelet aggregation response was determined using light transmittance aggregometry (LTA). The maximum platelet aggregation response was determined after 40 minutes. LNAs were purchased from Exiqon Life Sciences and consisted of nucleotide sequences with fully Locked Nucleic Acid and phosphorothioate-modified backbones. The used sequences were 5'-ATGTGCAGACTACTG-3' (i-hsa-miR-199a-3p) and 5'-ACGTCTATACGCCCA-3' (non-targeting control) for 15 nucleotides, 5'-CCAATATTTCTGTGCTGCT/CholT-3' for 19 nucleotides (i-miR-195a), 5'-AACACTGATTTCAAATGGTGC/CholT-3' for 21 nucleotides (i-hsa-miR-29b) and 5'-AAGGCAAGCTGACCCTGAAGTTT/CholT-3' for 23 nucleotides (nontargeting control). AntagomiR consisted of a 22 nucleotide sequence with 2'OMe-modified backbone, obtained from Fidelity Systems, Inc. The nontargeting sequence was 5`-A*A*GGCAAGCUGACCCUG-AA*G*U*U* Chol*T-3', with an asterisk denoting a phosphorothiate modification in the preceding nucleotide.
Statistics. Differences in the miRNA profile were assessed by principal component analysis (PCA). 2 The PCA plots were generated in R using the ggbiplot and ggplot2 packages. 5 MiRNA and platelet protein concentrations were log-transformed for analysis. Dependencies of miRNA concentrations on platelet spike-in were analyzed using linear mixed models featuring fixed effects in categorical form or in continuous form, random intercepts for subjects, and a general (unconstrained) covariance structure. Relationships between the concentrations of platelet proteins and of miRNAs were investigated using Spearman's rank correlation coefficient. Differences in platelet protein concentrations by the rs4636297 miR-126 polymorphism were tested by analysis of variance. Associations between the SNP and 219 plasma proteins were assessed by Kruskal-Wallis test, proteins were ordered by significance of association. A Kolmogorov-Smirnov test was used to determine the enrichment of the GO term "platelet activation" (ID GO:0030168). Stata version 12.0 MP was used for statistical analysis.
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Online Fig. I. NGS of plasma miRNAs. (A) 
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MiRNA relaBon between plasma samples. Each point on the plot corresponds to a parBcular miRNA; shown is the amount of that miRNA in sample 3 divided by the total number of miRNA reads in that sample (xaxis), and the amount of the same miRNA in sample 4 divided by the total number of miRNA reads in that sample (y-axis). The dashed red line represents the perfect diagonal, and the blue line represents the best linear fit across the data.
Online&Fig.&I&Quality&control&of&NGS.&(A)&qPCR%for%integrin%alpha%IIb%(ITGA2B),%CD45%and%beta%acAn%
(Actb)% in% PPP% and% PRP.% CT,% cycle% threshold;% N.D.,% not% determined.% (B)& BaseHcall% qualiAes% for% NGS% (sample%1,%PPP).%The%sequence%length%(bp,%xHaxis)%is%ploMed%against%the%quality%score%(yHaxis)%on%a% scale%from%1%to%40%with%40%being%the%highest%quality.%(C)&Histogram%of%sequence%lengths%for%sample%1% (PPP)% aQer% processing% for% adapter% removal% and% lower% bound% on% length.% The% shown% baseHcall% qualiAes%and%sequence%distribuAon%are%representaAve%for%all%samples%analysed.% Online Figure IV . MiRNA profile of platelet micropar:cles. Platelet micropar;cles were generated by s;mula;ng isolated human platelets with thrombin. MiRNAs were determined by microarray screening. The average Ct value was used as a normaliza;on control. Expression levels (2 -ΔCt ) were log transformed. The 11 selected miRNAs (highlighted in red font) are among the most abundant miRNAs in platelet micropar;cles.
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For the comparison of PPP and PRP, only miRNAs detected with more than 0.4 reads per million in each sample were taken into considera=on (n=224). Out of these 224 miRNAs, 203 had a higher number of rela=ve reads in
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Online Fig. V. Argonaute2 immunoprecipita5on . Ago2 complexes were precipitated from MEG-01 cell lysates using an Ago2 an=body or non-specific IgG as a control. As expected, miR-126 and miR-223 were enriched in Ago2 IPs (data shown as mean+SD, n=2 per condi=on) but we failed to detect RNY 3' and 5' fragments . Other small RNAs (U6, RNU48) were used as nega=ve controls. Rela=onship between the dependency of small RNA levels on platelets in the spike-in experiment (x-axis) and the correla=on of small RNA levels with platelet protein concentra=ons (SELP) in the general popula=on (y-axis) for 16 miRNAs and two RNY4 fragments. Ex vivo dependency of small RNA levels on platelets (see Fig. 4 ) was determined using increasing amounts of spikein into the PPP of n=4 volunteers each. In vivo correla=on between small RNAs and platelet-associated plasma proteins were determined in the popula=on-based Bruneck study (n=669, see Fig. 5A ). Lines are Deming regression lines and r denotes Pearson correla=on with 95% confidence interval. SELP, P-selec=n.
Online Figure VII . Associa3ons of SNP rs4636297 with miR-126 levels in plasma and serum. Circula)ng miR-126 levels and the genotype of rs4636297 were determined in the Bruneck cohort (n=628, Online Online Figure VIII . Dependency of plasma proteins on the rs4636297 SNP. Dependencies of plasma levels of 219 proteins on the AA genotype of the rs4636297 SNP were assessed by Wilcoxon test in the Bruneck cohort. Protein IDs are shown on the x-axis and P-values on the logarithmic y-axis. Black color indicates annotaJon with the GO term "platelet acJvaJon", gray color, no such annotaJon. Kolmogorov-Smirnov test yielded an enrichment P value of 0.019, indicaJng that annotated proteins and proteins not annotated differed in their distribuJons of P values for associaJon with the AA genotype. PF4, PPBP and SELP are highlighted in red. For independent validaJon of the ELISA data, mass-spectrometry-based measurements of PF4 were used for this analysis. For PPBP and SELP, only ELISA data were available (Fig. 6B , Online Table V) . PF4, platelet factor 4; PPBP, pro-platelet basic protein; SELP, P-selecJn.
Enrichment P=0.019 A1BG  A2AP  A2GL  A2MG  AACT  AFAM  ALBU  AMBP  ANGT  ANT3  APOA  APOA1  APOA2  APOA4  APOB  APOC1  APOC2  APOC3  APOD  APOE  APOH  APOL1  APOM  C1QB  C1QC  C1R  C1S  C4BPA  CBG  CD5L  CERU  CFAB  CFAH  CFAI  CLUS  CO2  CO3  CO5  CO8A  CO9  F13A  FBLN1  FETUA  FIBA  FINC  GELS  GPX3  HBD  HEMO  HEP2  HPT  HPTR  HRG  IC1  IGHA1  IGHA2  IGHG1  IGHG2  IGHG3  IGHM  ITIH1  ITIH2  ITIH4  KLKB1  KNG1  PEDF  PGRP2  PLF4  PLMN  RET4  SAA4  SEPP1  SHBG  TETN  THBG  THRB  TRFE  TTHY  VTDB  VTNC  ZA2G  AM  CD40−L  GDF− LNA-126 (B) or the respecBve controls. MiRNA expression was normalised to endogenous U6. Graphs represent mean+SEM (n=4 per condiBon), asterisks denote staBsBcal significance in a two-way ANOVA with Bonferroni post-test (***, p<0.001). Online Table III . AnKplatelet medicaKon in the ACS cohort (n=125). Plasma was taken 30 days a]er the acute event when the inflammaDon associated with the acute injury has receded and anD-platelet drugs had been administered for a month. Importantly, none of the ACS paDents had received heparin at the Dme of sampling. Table V . Protein associations with the rs4636297 AA genotype. In the Bruneck cohort, 219 plasma proteins were measured and for each protein levels were compared between subjects with the AA genotype of the SNP rs4636297 and subjects with other genotypes. P values were derived from Wilcoxon-MannWhitney tests and proteins are ranked ascending by P value. Three measures of effect size are shown: Median ratio refers to the ratio of the median concentration in AA subjects over that in other subjects; mean ratio to an analogous ratio of means; and median difference to the difference in medians scaled by the overall interquartile range. The last column indicates whether a protein has the GO annotation "platelet activation". Proteins tested by ELISA (Fig. 6B) Table VI . Selec/on of miR-126 targets and platelet-related genes for gene expression analysis. Validated miR-126 targets (green) and targets of miR-126 predicted by at least 5 out of 9 algorithms available in miRWalk 7 (blue) were selected if they also had a reported role in platelet funcDon. References are given for the experimental confirmaDon as miR-126 targets and for the involvement of the target protein in platelet funcDon. The column "Platelet web" lists whether a target was found in the proteome, serial analysis of gene expression (SAGE) analysis or both according to the Platelet web database. 8 
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